文献速递类风湿关节炎

接受抗白细胞介素-6治疗的类风湿关节炎患者乙型肝炎病毒再激活:系统评价与Meta分析

HBV reactivation in patients with rheumatoid arthritis treated with anti-interleukin-6: a systematic review and meta-analysis.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

该系统评价与Meta分析检索了截至2023年1月28日的文献,纳入19篇文章共372例慢性乙型肝炎或乙型肝炎病毒已清除感染的类风湿关节炎患者,评估抗白细胞介素-6治疗下乙型肝炎病毒再激活风险。慢性乙型肝炎患者总体再激活风险为6.7%,未接受抗病毒预防时升至37%;乙型肝炎病毒已清除感染者再激活率接近0%,所有再激活者经抗病毒和/或停药均成功处理。

要点

  • 慢性乙型肝炎的类风湿关节炎患者接受抗白细胞介素-6治疗总体乙型肝炎病毒再激活风险为6.7%。
  • 慢性乙型肝炎且未抗病毒预防者再激活风险升至37%,抗病毒预防可降低风险。
  • 乙型肝炎病毒已清除感染者再激活率接近0%,无论是否抗病毒预防。

核心结论

  • 在慢性乙型肝炎的类风湿关节炎患者中,抗白细胞介素-6治疗伴随显著的乙型肝炎病毒再激活风险,使用抗病毒预防时风险降低。
  • 在乙型肝炎病毒已清除感染的类风湿关节炎患者中,乙型肝炎病毒再激活风险似乎极低。
  • 需要大规模、设计良好的研究(对照试验或多中心/国际观察性研究)来进一步验证这些结果。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Scopus和EMBASE,无日期限制,最后更新于2023年1月28日。
  • 合并所有数据库结果并排除重复,排除非英文文章、病例报告、立场文章、评论和儿科研究。
  • 初检获427篇文章,经排除后最终纳入19篇文章,共372例慢性乙型肝炎或乙型肝炎病毒已清除感染的类风湿关节炎患者。

主要发现

  • 慢性乙型肝炎的类风湿关节炎患者总体乙型肝炎病毒再激活风险为6.7%。
  • 仅纳入慢性乙型肝炎且未接受抗病毒预防的类风湿关节炎患者时,再激活风险升至37%。
  • 乙型肝炎病毒已清除感染的类风湿关节炎患者中,再激活率接近0%,与是否抗病毒预防无关。
  • 这些研究中所有发生乙型肝炎病毒再激活的类风湿关节炎患者均经抗病毒治疗和/或停药成功处理。

关键数值与推荐

  • 慢性乙型肝炎的类风湿关节炎患者总体乙型肝炎病毒再激活风险为6.7%。
  • 慢性乙型肝炎且无抗病毒预防的类风湿关节炎患者乙型肝炎病毒再激活风险为37%。
  • 乙型肝炎病毒已清除感染的类风湿关节炎患者乙型肝炎病毒再激活率接近0%, irrespective of antiviral prophylaxis。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要大规模、设计良好的研究(对照试验或多中心/国际观察性研究)来进一步验证这些结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to assess the possibility of HBV reactivation (HBVr) in patients with RA under anti-IL-6 treatment. METHODS: Using PubMed, Scopus and EMBASE, we performed a systematic literature search for articles related to HBVr in RA patients under anti-IL-6 treatment. The search was performed with no date limits and was last updated 28 January 2023. The results from all the databases were combined and duplicates were excluded, as were non-English articles, case reports, position articles, comments, and paediatric studies. RESULTS: Our initial search led to 427 articles; 28 were duplicates, 46 non-English, 169 reviews, 31 books/letters, 25 case reports, and 88 irrelevant to the meta-analysis aim; 21 were excluded due to inadequate information, leaving 19 articles, with a sum of 372 RA patients with chronic HBV (CHB) or resolved HBV infection, for further analysis. The overall risk for HBVr in RA patients with CHB was 6.7%, increasing to 37% when only RA patients with CHB and no antiviral prophylaxis were included. On the contrary, HBVr was close to 0% in RA patients with resolved HBV infection, irrespective of antiviral prophylaxis. All RA patients experiencing HBVr in these studies were successfully managed with antiviral treatment and/or drug withdrawal. CONCLUSION: Overall, anti-IL-6 treatment comes with a significant risk of HBVr in RA patients with CHB; risk is diminished when antiviral prophylaxis is used. In contrast, in RA patients with resolved HBV infection, the risk of HBVr seems to be extremely low. Large, well-designed studies (either controlled trials or multicentre/international observational studies) are warranted to further validate these results.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Katelani S, Fragoulis GE, Bakasis AD, et al. HBV reactivation in patients with rheumatoid arthritis treated with anti-interleukin-6: a systematic review and meta-analysis. Rheumatology (Oxford). 2023. PMID: 37871924. doi:10.1093/rheumatology/kead243

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。